Antipsychotics and Risk of Hyperglycemic Emergencies

Summary

The purpose of this study is to determine whether the use of atypical antipsychotic medication increases the risk of hospitalization for a hyperglycemic emergency.

The investigators will carry out separate population-based cohort studies using administrative health databases in eight jurisdictions in Canada and the UK. Cohort entry will be defined by the initiation of a new antipsychotic medication. Follow-up will continue until hospitalization for a hyperglycemic emergency or the end of 365 days. The results from the separate sites will be combined to provide an overall assessment of the risk of hyperglycemic emergencies among new users of various antipsychotic drugs.

Conditions

• Psychotic Disorders
• Schizophrenia
• Schizoaffective Disorder
• Bipolar Disorder
• Diabetes Mellitus, Type 2

Interventions

DRUG

Olanzapine

Exposure to olanzapine (ATC N05AH03) will be defined as a prescription for olanzapine on the date of cohort entry.

DRUG

Risperidone

Exposure to risperidone (ATC N05AX08) will be defined will be defined as a prescription for risperidone on the date of cohort entry.

DRUG

atypical antipsychotics (other)

Exposure to other atypitical antipsychotics (ATC N05AH02, N05AH04, N05AE04, N05AX13, N05AX12) will be defined will be defined as a prescription for an atypical antipsychotic other than olanzapine on the date of cohort entry.

DRUG

typical antipsychotics

Exposure to typical antipsychotics (M03BB02, N05AA01, N05AF03, N05AF01, N05AB02, N05AG01, N05AD01, N05AA02, N05AH01, N05AC03, N05AB03, N05AG02, N05AC04, N07XX06, N05AB05, N05AB08, N05AC02, N05AF04, N05AB06, N05AF05) will be defined as a prescription for a typical antipsychotic on the date of cohort entry.

Sponsors & Collaborators

• Drug Safety and Effectiveness Network, Canada

  collaborator OTHER

• Canadian Institutes of Health Research (CIHR)

  collaborator OTHER_GOV

• Canadian Network for Observational Drug Effect Studies, CNODES

  lead OTHER

Principal Investigators

• Lorraine Lipscombe, MD, MSc · Women's College Hospital, Women's College Research Institute

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2012-04-30

Primary Completion

2012-12-31

Completion

2012-12-31

Countries

• Canada

Study Locations